A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

Prior treatment

• Any prior use of Repatha® or other proprotein convertase subtilisin/kexin type 9 inhibition treatments within past 6 months prior to enrollment.
• Participants currently enrolled in another study involving any investigational procedure, device or drug.

Other illness

• Stroke within past 1 month.
• Known hemorrhagic stroke at any time.
• Stroke due to thromboembolic event.
• Participants prescribed Repatha® with a history of severe hypersensitivity or allergy to any subsidiary.

• Adult participants ≥ 18 years of age.
• Participants or participant's legally authorized representative has provided informed consent to participate in this study.
• Participants who meet one of the following:
• Prescribed Repatha® in addition to an existing SOC treatment according to local guidelines and approved label.
  • OR
• Already received SOC treatment prior to enrollment.
• Participants with ANY of the following.
• Diagnosis of MI OR stroke within 2 years before enrollment.
• 2 MIs OR ≥ 2 strokes OR (≥ 1 MI AND ≥ 1 stroke) any time before enrollment.
• Diagnosis of (MI OR stroke) AND diabetes.
• Diagnosis of (MI OR stroke) AND documented multivessel disease (defined as \> 50% stenosis of ≥ 2 major coronary arteries on coronary angiography or coronary artery contrast enhanced computed tomography).
• Diagnosis of symptomatic peripheral arterial disease.
• Most recent fasting LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L) or nonhigh-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (≥ 2.6 mmol/L) within 6 months prior to enrollment.
• Most recent fasting triglycerides ≤ 400 mg/dL (≤ 4.5 mmol/L) within 6 months prior to enrollment.